New study probes protein clues in PCOS and heart disease link
NCT ID NCT07396402
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will measure levels of two proteins, SCUBE-1 and SCUBE-3, in the blood of women with polycystic ovary syndrome (PCOS) and compare them to healthy women. Researchers want to see if these proteins are linked to inflammation and a higher risk of heart problems. About 56 women aged 18-35 will take part. The goal is to better understand the connection between PCOS and heart disease, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 56 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 35 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female subjects aged 18-35 years * Diagnosis of polycystic ovary syndrome (normoinsulinemic or hyperinsulinemic) * Availability of basal hormonal evaluation and oral glucose tolerance test * Healthy women for control group * Written informed consent Exclusion Criteria: * Pregnancy * History of cardiovascular disease * Diabetes mellitus or impaired glucose tolerance * Hypertension * Significant hepatic or renal disease * Other endocrine disorders * Neoplastic diseases * Psychiatric disorders * Autoimmune diseases * Shift work * Obesity * Refusal to sign informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Insulin resistance are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, 00168, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Insulin may quiet the immune alarm tied to heart disease
- Can weightlifting beat cardio for blood sugar in pregnancy?
- Strawberries as medicine? trial tests whether the fruit can calm inflammation and boost insulin response
- Can cutting carbs curb metabolic syndrome in teens?
- A pill that could replace the needle: new test for insulin reserve
- Can a Patient's own blood plasma kickstart ovulation in PCOS?